• EE12 A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France

    Dec 1, 2025, 00:00

  • HTA274 Pricing Analysis of Value-Added Medicines (VAMs) in Europe: A Call for Recognition of Patient-Centric Innovation

    Dec 1, 2025, 00:00

  • RWD31 Characterization of a Large-Scale Real-World Data Sour Impact of Linking Closed Claims With Electronic Health Record Data

    Dec 1, 2025, 00:00

  • MSR102 Exploring Artificial Intelligence's (AI's) Role in Literature Screening: A Comparative Analysis Paving the Way for More Efficient Evidence Synthesis

    Dec 1, 2025, 00:00

  • PCR137 Improving Time to Patient: Insights From the Canadian Cancer Treatment Hackathons

    Dec 1, 2025, 00:00

  • EE6 A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden

    Dec 1, 2025, 00:00

  • CO77 Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • P3 Zoom In: Uncovering Clinical Nuance in Simplified Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • HTA95 Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages

    Dec 1, 2025, 00:00

  • HPR101 From Cost Containment to Modernization: Market Access Updates Across the EU4 and the UK in 2025

    Dec 1, 2025, 00:00

  • EE179 Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation From the Spanish Healthcare System Perspective

    Dec 1, 2025, 00:00

  • RWD73 Economic Burden of Type 1 Diabetes Mellitus After Disease Onset: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • HPR236 Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States

    Dec 1, 2025, 00:00

  • OP7 Exploring Value in Healthcare: Patient Satisfaction in Spain Before and After the Pandemic

    Dec 1, 2025, 00:00

  • CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment

    Dec 1, 2025, 00:00

  • EE117 Burden Of Disease, Healthcare Resource Use and Costs of Respiratory Syncytial Virus Among Adults in Spain in 2021-2023 in the Hospital Setting: A Real-World Retrospective Observational Study of Four Hospitals

    Dec 1, 2025, 00:00

  • EE314 Cost-Utility of Protocoled Practice Nurse-Led Care for Children With Asthma in Primary Care

    Dec 1, 2025, 00:00

  • RWD56 Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability

    Dec 1, 2025, 00:00

  • HPR153 Orphan Drugs Availability in Israel: A Base for Policy Development

    Dec 1, 2025, 00:00

  • PCR253 Understanding Patient Priorities in Psoriasis Treatment: A Review of Key Decision-Making Drivers

    Dec 1, 2025, 00:00

  • MSR85 Empirical Evidence on Impact by Accounting for Cluster Effect Within Patients in Cohort Studies Evaluating Comparative Effectiveness of Dental Treatments: A Meta-Epidemiological Study

    Dec 1, 2025, 00:00

  • EE397 Economic Impact of Emicizumab vs. On-Demand Therapy With Bypassing Agents in Patients With Hemophilia A With Inhibitors in Mexico

    Dec 1, 2025, 00:00

  • HTA322 The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries

    Dec 1, 2025, 00:00

  • EE447 Evaluating the Societal and Economic Impact of Immunotherapy for Melanoma Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • RWD81 Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024

    Dec 1, 2025, 00:00

  • EPH65 Drivers of Improvement in Observed Survival in Malignant Cancer Sites: A Cancer Registry Analysis

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • CO97 Enterocutaneous Fistula (ECF) and Economic Burden Preliminary Data From a HEOR Model of a Laboratory (LAB) Experiment Plus Potential Cost Avoidance

    Dec 1, 2025, 00:00

  • PCR58 Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version

    Dec 1, 2025, 00:00

  • RWD173 Short- and Longer-Term Healthcare Resource Utilization and Related Costs With Psoriasis in Brazilian Private Market

    Dec 1, 2025, 00:00

  • MSR165 Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers

    Dec 1, 2025, 00:00

  • EE411 Enhancing Operational Efficiency: Time and Cost Savings of a Minimally Invasive Vascular Closure Device in Germany

    Dec 1, 2025, 00:00

  • HTA292 Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain

    Dec 1, 2025, 00:00

  • EE627 Quantifying the Fiscal Benefits of Obesity Prevalence Reduction in China: A Public Economic Perspective

    Dec 1, 2025, 00:00

  • PCR230 The Estimation of Utility Weights From the Rett Syndrome Behavior Questionnaire

    Dec 1, 2025, 00:00

  • HPR204 The Impact of the Introduction of Diagnosis-Related Groups (DRG)-Based Hospital Financing on the Performance of Romanian Hospitals

    Dec 1, 2025, 00:00

  • EE390 Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management

    Dec 1, 2025, 00:00

  • EPH128 Hospital Systemic Treatment for HepatoCarcinoma: The HOSTHECA Study

    Dec 1, 2025, 00:00

  • HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024

    Dec 1, 2025, 00:00

  • EPH36 Cardiovascular Event Rates and Mortality Among Secondary-Prevention Hypercholesterolemia Patients in Japan

    Dec 1, 2025, 00:00

  • CO232 Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • MT35 Potential Impacts of Improvement in Turnaround Time

    Dec 1, 2025, 00:00

  • EE55 Assessing Conditional Cash Transfers for Tuberculosis Patients in India: An Extended Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HTA211 Is NICE’s Proportionate Approach Achieving Its Objective: Analysis of Time to Access for Cost Comparison vs. Single Technology Appraisal

    Dec 1, 2025, 00:00

  • HTA103 Defining Unavoidable Uncertainty in HTA: Towards More Flexible and Adapted Approaches for Promising Treatments

    Dec 1, 2025, 00:00

  • CO54 Comparative Efficacy and Safety of Avacincaptad Pegol vs. Pegcetacoplan in Treatment of Geographic Atrophy: Insights From a Multilevel Network Meta-Regression

    Dec 1, 2025, 00:00

  • SA60 Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?

    Dec 1, 2025, 00:00

  • EPH175 Patient-Relevant Benefits From Ixekizumab Treatment in Patients With Psoriasis: Data From the German National Psoriasis Registry PsoBest

    Dec 1, 2025, 00:00

  • EE74 Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective

    Dec 1, 2025, 00:00

  • HPR167 Publicly Funded Fertility Preservation Services for Medical Reasons in Selected Countries

    Dec 1, 2025, 00:00

  • Dec 1, 2025, 00:00

  • EE208 Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective

    Dec 1, 2025, 00:00

  • HTA241 Navigating Clinical Trial Design Under the EU Health Technology Assessment Regulation

    Dec 1, 2025, 00:00

  • CO230 Systematic Review of Prognostic Factors and Treatment Effect Modifiers for Transthyretin Amyloid Cardiomyopathy

    Dec 1, 2025, 00:00

  • EE375 Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review

    Dec 1, 2025, 00:00

  • HPR93 Fair Pricing of Innovative Medicines From Definition to Application in CAR-T Cell Therapy

    Dec 1, 2025, 00:00

  • EE692 The Cost-Effectiveness of an Artificial Intelligence Software for Stroke Imaging and Treatment Decisions in NHS Hospitals

    Dec 1, 2025, 00:00

  • EE52 Analysis of the Fiscal and Socioeconomic Impact of a National Social Program to Support In Vitro Fertilization in Romania: A Generational Accounting Model

    Dec 1, 2025, 00:00

  • MSR160 Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements

    Dec 1, 2025, 00:00

  • MSR9 A Retrieval-Augmented Generation (RAG)-Based Framework to Automate Report Writing for Systematic Literature Reviews (SLRs) in Evidence Synthesis

    Dec 1, 2025, 00:00

  • PCR169 Patient and Caregiver Recommendations for Person-Centered Oncology Clinical Trial Design: A Qualitative Study

    Dec 1, 2025, 00:00

  • EE455 Exploratory Assessment of the Societal Impact of Changing Informal Care Hours in the Netherlands

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • MSR32 Applying the Delphi Method: A Scoping Review in Healthcare Decision Making and HEOR

    Dec 1, 2025, 00:00

  • EE706 The Economic Value of Diagnostic Strategies in Hepatitis D: A Methodological Review of Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • CO246 The Prevalence of COAs and DHTs for Studying Sleep Disorders in Clinical Trials

    Dec 1, 2025, 00:00

  • HTA81 Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?

    Dec 1, 2025, 00:00

  • SA76 Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials

    Dec 1, 2025, 00:00

  • EE97 Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective

    Dec 1, 2025, 00:00

  • HTA13 A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal

    Dec 1, 2025, 00:00

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • MSR221 What Is the Value of Large Language Models for Improving Extraction and Interpretation of Efficiency Data From French Commission Dévaluation Économique et de Santé Publique (CEESP): Decisions on Breast Cancer Medications?

    Dec 1, 2025, 00:00

  • MSR188 Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation

    Dec 1, 2025, 00:00

  • PCR258 Use of EORTC Item Lists for Patient-Reported Outcome Measurement in Industry-Sponsored Research: A Three-Year Snapshot of Study Characteristics

    Dec 1, 2025, 00:00

  • CO126 Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review

    Dec 1, 2025, 00:00

  • CO205 Real-World Evidence on the Broader Benefits of GLP-1RA-Based Therapies: A Global Targeted Literature Review

    Dec 1, 2025, 00:00

  • CO197 Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nirogacestat in Patients With Desmoid Tumors

    Dec 1, 2025, 00:00

  • EPH223 Survey of Depression Literacy and Help-Seeking Behavior Among Secondary School Students

    Dec 1, 2025, 00:00

  • HTA192 IMF: The Innovative Medicines Fund or the Interim Medicines Fund?

    Dec 1, 2025, 00:00

  • HSD83 Patterns Of Adoption And Diffusion Of Biological Therapies In Inflammatory Bowel Disease: Patient-Centric Insights From Israel

    Dec 1, 2025, 00:00

  • HTA296 Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • PCR118 Health-Related Quality of Life in Patients With Metastatic Urothelial Cancer: Results of a Cross-Sectional Survey in Europe

    Dec 1, 2025, 00:00

  • PCR23 Assessing the Sensitivity of EQ-5D-5L and AQoL-4D to Disease Severity in Von Willebrand Disease: Findings From UK Cohort of the PIVOT-vWD Study

    Dec 1, 2025, 00:00

  • EPH254 The Role of Body Fat in the Regulation of Male Fertility

    Dec 1, 2025, 00:00

  • RWD116 Leveraging a Multicountry Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe

    Dec 1, 2025, 00:00

  • CO214 Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EPH238 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Nonsquamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • HTA334 The Uptake of R in NICE HTA: Insights From Technology Assessment Groups

    Dec 1, 2025, 00:00

  • EE162 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Dec 1, 2025, 00:00

  • HTA221 Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood

    Dec 1, 2025, 00:00

  • HSD104 Strengthening Routine Childhood Immunization Post-COVID: Global Strategies to Improve Coverage and Equity

    Dec 1, 2025, 00:00

  • HPR9 A Review of the UK's International Recognition Procedure and Its Role in Expediting Access to Innovative Treatments

    Dec 1, 2025, 00:00

  • HTA242 Navigating Evidence Requirements for Joint Clinical Assessment (JCA): Practical Considerations for Systematic Literature Review (SLR) and Indirect Treatment Comparisons (ITCs)

    Dec 1, 2025, 00:00

  • EE311 Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea

    Dec 1, 2025, 00:00

  • MT18 From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe

    Dec 1, 2025, 00:00

  • EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study

    Dec 1, 2025, 00:00

  • PT9 Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines

    Dec 1, 2025, 00:00

  • EE516 Healthcare Resource Utilization and Time Burden in Patients With Myelodysplastic Syndromes/Neoplasms Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

    Dec 1, 2025, 00:00

  • RWD108 Integrating Agentic AI With LLM Workflows for Cohort Comparison in Healthcare Analytics

    Dec 1, 2025, 00:00

  • PCR42 Characterizing the UK Population Living With Von Willebrand Disease: Foundational Data for Health Economics and Outcomes Research

    Dec 1, 2025, 00:00

  • SA10 Alternative Evidence Generation Approaches for Rare Diseases: Addressing HEOR and Healthcare Decision-Making Challenges

    Dec 1, 2025, 00:00

  • EE424 Estimating the Clinical and Economic Value of Aztreonam-Avibactam for the Treatment of Metallo-Beta-Lactamase–Producing Carbapenem- Resistant Enterobacterales Infections in China: Adopting the STEDI Value Framework

    Dec 1, 2025, 00:00

  • EE530 Impact Of Dupilumab Treatment On Healthcare Resource Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • CO5 A Systematic Review and Network Meta Analysis of Pharmacologic Disease-Modifying Therapies for Early Alzheimer's Disease

    Dec 1, 2025, 00:00

  • HTA93 Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer

    Dec 1, 2025, 00:00

  • EE656 Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings

    Dec 1, 2025, 00:00

  • HTA44 Assessing Readiness for the EU-HTA Regulation: Insights From Market Access Experts Across Europe

    Dec 1, 2025, 00:00

  • CO4 A Systematic Review (SR) and Network Meta-Analysis (NMA) of Cystic Fibrosis Transmembrane Conductance Receptor (CFTR) Modulator Therapies and Established Clinical Management (ECM) Using Percent Predicted Forced Expiratory Volume in One ...

    Dec 1, 2025, 00:00

  • EE551 Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review

    Dec 1, 2025, 00:00

  • HSD78 Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia

    Dec 1, 2025, 00:00

  • RWD103 Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis

    Dec 1, 2025, 00:00

  • EPH265 Tropical Virus in Fran Dengue Cases on the Rise

    Dec 1, 2025, 00:00

  • PCR93 Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews

    Dec 1, 2025, 00:00

  • PCR89 Exploration of the Utility of Linguistic Validation Cognitive Debriefing Interviews in Generating Evidence for Adding or Modifying Source COA Content

    Dec 1, 2025, 00:00

  • EE100 Budget Impact Analysis of the EPOCA Telemonitoring System for Elderly Patients in France

    Dec 1, 2025, 00:00

  • RWD102 Improving Identification of Patients With Rare Diseases Through Indirect Linkage Between French Medico-Administrative Claims Database (SNDS) and National Rare Disease Registry (BNDMR) in Fran A Dual-Population Study

    Dec 1, 2025, 00:00

  • EE242 Cost-Effectiveness of Connected Injection Device for Pediatric Growth Hormone Deficiency in Spain: A Scenario-Based Microsimulation Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • HSD61 Impact on Prescribing Choice Following the Identification of Preferred Continuous Glucose Monitoring Sensors in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana

    Dec 1, 2025, 00:00

  • OP23 Streamlining Cancer Treatment Pathways: Organizational Responses to Rising Chemotherapy Volumes

    Dec 1, 2025, 00:00

  • MSR195 The AI-in-RWE Transparency (AIRT) Checklist: Essential and Desirable Standards for AI-Enhanced Real-World Evidence

    Dec 1, 2025, 00:00

  • EE257 Cost-Effectiveness of In-Hospital Motivational Smoking Cessation Counseling and Proactive Referral to Primary Care Follow-up

    Dec 1, 2025, 00:00

  • P53 Exploring the Ability of Generative AI to Interpret and Report Comprehensive NMA Results: A Step Towards the Automation of NMA Reports

    Dec 1, 2025, 00:00

  • HTA124 Enhancing Patient Involvement in European Health Technology Assessment (HTA): From Inconsistent National Practices to Systematic Engagement in Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • EE672 Stop Ignoring Missing Patients the Hidden Impact of Ignoring Missing Data in Health State Utility Estimation

    Dec 1, 2025, 00:00

  • MSR148 Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices

    Dec 1, 2025, 00:00

  • EPH215 Site-Specific Wastewater-Based Surveillance in Early Detection of COVID-19 New Cases and Prediction of Mass Testing Outcomes in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • EE590 Modeling Treatment-Free Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukemia: Assumptions, Methodology, and Projections

    Dec 1, 2025, 00:00

  • SA56 Integrating Stakeholder Insights Into Thematic Analysis: Enhancing Efficiency and Supporting HEOR

    Dec 1, 2025, 00:00

  • HTA259 One Trial, Two Clocks: Coordinating EMA Assessment and Complementary EU HTA Evidence

    Dec 1, 2025, 00:00

  • EE552 Indirect Treatment Comparisons in Economic Evaluations Submitted to the French Health Authority (CEESP) Since 2014

    Dec 1, 2025, 00:00

  • MSR179 Reducing the Rare Disease Diagnostic Odyssey: Identifying Potential Pulmonary Arterial Hypertension Patients Using the Problem List of Diagnosed Patients

    Dec 1, 2025, 00:00

  • HPR146 Navigating the Influence of Traditional Chinese Medicine (TCM) on the Positioning of New Treatments in China: A Review of TCM Inclusion in Clinical Guidelines

    Dec 1, 2025, 00:00

  • HPR144 Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland

    Dec 1, 2025, 00:00

  • EE715 The Impact of Real-World Standard-Dose Influenza Vaccine Effectiveness on the Cost-Effectiveness of High-Dose Influenza Vaccine: A Case Study in Japan

    Dec 1, 2025, 00:00

  • EE718 The Ongoing Challenge of Clostridioides Difficile Infection in Austria: Economic Evaluation of Two Recommended Treatment Pathways

    Dec 1, 2025, 00:00

  • EE422 Estimating Quality-Adjusted Life Expectancy by Ethnicity for Application in Distributional Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE187 Cost Savings From Patient Preference-Based Allocation of High-Efficacy Therapies for MS: Evidence From Switzerland

    Dec 1, 2025, 00:00

  • MSR120 How Chinese Restaurants Can Help With Robust Preference Insights: A Novel Dirichlet Mixture Model to Account for Complex Heterogeneity in Individual Preference Weights

    Dec 1, 2025, 00:00

  • CO98 Epidemiological Study of Pulmonary Hypertension in Patients With Interstitial Lung Diseases (PH-ILD) in Gree A Retrospective Multicenter Study

    Dec 1, 2025, 00:00

  • PT29 From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding

    Dec 1, 2025, 00:00

  • EE197 Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China

    Dec 1, 2025, 00:00

  • PCR175 Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care

    Dec 1, 2025, 00:00

  • RWD24 Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • MT7 Assessing the Economic Impact of a Robotic-Assisted Solution vs. a Manual Approach in Total Knee Arthroplasty in the UK

    Dec 1, 2025, 00:00

  • EE329 Digital Health Literacy, Engagement, and the Economics of Health Behavior: Evidence from the US HINTS Survey

    Dec 1, 2025, 00:00

  • HPR131 Launches of Oncology Products in LATAM vs. the United States

    Dec 1, 2025, 00:00

  • HPR125 Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024

    Dec 1, 2025, 00:00

  • PCR150 Looking Back to Go Forward: Reintegrating Scientific Considerations Into eCOA Design and Implementation

    Dec 1, 2025, 00:00

  • EE3 A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar

    Dec 1, 2025, 00:00

  • PCR261 Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)

    Dec 1, 2025, 00:00

  • HTA9 A Matching-Adjusted Indirect Comparison (MAIC) of Rucaparib vs. Niraparib in the Maintenance Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (aOC) After Response to First-Line Platinum-Based Chemotherapy

    Dec 1, 2025, 00:00

  • MT46 Value of in Vitro Diagnostic IVD Tests in Health Society and Economy in Portugal

    Dec 1, 2025, 00:00

  • HTA354 Validation of a Natural Language Processing Solution (REALLI) Compared to Manual Review by Physicians of Electronic Health Records (EHR) From Patients With HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EPH87 Estimating the Eligible Population for Anti-Amyloid Therapy in Finland

    Dec 1, 2025, 00:00

  • PCR141 Integrating PROMs Into Real-World Ophthalmology Practi A Pilot Project on Neovascular AMD

    Dec 1, 2025, 00:00

  • EE169 Cost-Effectiveness of Nemolizumab in the Treatment of Patients With Moderate-to-Severe Prurigo Nodularis in Italy

    Dec 1, 2025, 00:00

  • HPR141 Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study

    Dec 1, 2025, 00:00

  • EE287 Costs and Number Needed to Treat (NNT) to Achieve Improvements With C5 Inhibitors in Generalized Myasthenia Gravis From the Japanese Healthcare Perspective: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO159 Lipid-Lowering Prescription Patterns After a Nonfatal Acute Coronary Syndrome: The Impact of Real-World Evidence on Clinical Practice With LATINO-ACS 2.0

    Dec 1, 2025, 00:00

  • HSD6 Analysis of Pharmacists' Awareness on Post COVID-19 Conditions and Implementation in Postgraduate Education in Ukraine

    Dec 1, 2025, 00:00

  • EE616 Pricing Implications of Subcutaneous Reformulations Following Intravenous Launches: A Multicountry Analysis

    Dec 1, 2025, 00:00

  • PT12 Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis

    Dec 1, 2025, 00:00

  • EE221 Cost-Effectiveness Analysis of the Prostate Health Index (PHI) Test After a Prostate-Specific Antigen (PSA) Test in UK

    Dec 1, 2025, 00:00

  • P48 Empirical Comparison of Subjective Well-Being and Health-Related Quality of Life Measures in Australian Adolescents

    Dec 1, 2025, 00:00

  • HPR202 The Impact of Annual Price Revision Based on External Reference Pricing on Medicines Between 2012 and 2023 in Portugal

    Dec 1, 2025, 00:00

  • PCR20 Are You Implementation Ready? An Alternative Patient And Healthcare System-Centered Model For Pharma

    Dec 1, 2025, 00:00

  • HPR170 Real-World Data for External Controls: Insights From EMA Regulatory Submissions

    Dec 1, 2025, 00:00

  • HTA314 The Development of the Multicriteria Decision Analysis in Specialized Burn Care: The Methodological Process

    Dec 1, 2025, 00:00

  • EPH48 Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study

    Dec 1, 2025, 00:00

  • HPR173 Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • CO194 Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Illness Among High-Risk Adults Aged 18-59 Years in Germany

    Dec 1, 2025, 00:00

  • EPH268 Underlying Systemic Motifs That Prevent Diabetes Patients From Seeking and Utilizing Health Services in a Country With a High Prevalence of Diabetes

    Dec 1, 2025, 00:00

  • EE462 Feasibility Evaluation of Claims Database: Best Practices and Case Study for a Comparative Analysis of Robotic-Assisted Colorectal Surgery in Germany

    Dec 1, 2025, 00:00

  • EE154 Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence

    Dec 1, 2025, 00:00

  • HSD23 Characteristics of DNAR Orders Among Non-Critically Ill Extremely Elderly Patients Admitted to a University Hospital in Japan

    Dec 1, 2025, 00:00

  • SA107 Zero-Shot RCT Identification Using Large Language Models: A Comparative Study With the Cochrane Classifier

    Dec 1, 2025, 00:00

  • CO182 Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • CO140 Impact of Pharmacotherapy Adherence on the Reduction of Major Adverse Cardiovascular Events (MACE) Among Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • EE150 Conceptual Approach to Economic Modeling in Retinal Diseases: A Review and Critique of Two NICE Clinical Guidelines

    Dec 1, 2025, 00:00

  • EE582 Model Behavior: A Health Economics Checklist for Sales Models

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • EPH197 Public Health and Economic Impact of RSVpreF Vaccination Among Older Adults in Latin America and the Caribbean

    Dec 1, 2025, 00:00

  • HTA210 Integration of Germany’s AMNOG Framework With the Joint Clinical Assessment Process

    Dec 1, 2025, 00:00

  • EE518 Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • CO128 Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada

    Dec 1, 2025, 00:00

  • EE201 Cost-Effectiveness Analysis of GAAD Algorithm for Hepatocellular Carcinoma Surveillance of Cirrhotic Patients Using Italian Real-World Data

    Dec 1, 2025, 00:00

  • HTA239 Multicriteria Health Technology Assessments for High-Cost Oncology Drugs in Peru: A Cross-Sectional Study of RENETSA Records 2023-2024

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • EPH69 Effectiveness of HPV Vaccination Across Europe: A Comparative Analysis

    Dec 1, 2025, 00:00

  • CO130 Health-Related Quality of Life (HRQoL) Impacts in Individuals With Hypophosphatasia (HPP): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • MSR191 Survival Extrapolations With and Without Incorporating External Eviden Evaluating the Performance of Bayesian M-Spline Models vs. Parametric Models in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Dec 1, 2025, 00:00

  • HTA358 Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases

    Dec 1, 2025, 00:00

  • EE412 Enhancing Palliative Care in Intensive Care Units (EPIC) Trial Design of the Health Economic Substudy

    Dec 1, 2025, 00:00

  • HTA194 Impact of the Introduction of the NICE Severity Modifier on HTA Outcomes of Oncology and Non-oncology Orphan Drugs

    Dec 1, 2025, 00:00

  • HSD45 Ethical Implications of the Use of Artificial Intelligence (AI) Based Technologies for Medical Image Classification Systems in Screening: A Qualitative Systematic Review

    Dec 1, 2025, 00:00

  • SA95 The Journey to Diagnosis for Patients With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • EE122 CAR-NK Cell Therapy for Ovarian Cancer Treatment in the First Relapse: Assessing Conditions Needed for Cost-Effectiveness in the Netherlands Using Early Health-Economic Modeling

    Dec 1, 2025, 00:00

  • EE635 Real-World Cost-Utility of Faricimab vs. Current and Future Anti-VEGF Therapies in Patients With Neovascular Age-Related Macular Degeneration in Italy

    Dec 1, 2025, 00:00

  • MSR100 Evaluation of the Use of ChatGPT in Data Extraction for Systematic Literature Reviews: Friend, Foe, or Fiction?

    Dec 1, 2025, 00:00

  • EE442 Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective

    Dec 1, 2025, 00:00

  • EPH172 Objective Real-World Caregiver Costs and Lost Time for Absences and Family Medical Leaves in the United States for Employees Whose Spouses Have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

    Dec 1, 2025, 00:00

  • MSR156 NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights

    Dec 1, 2025, 00:00

  • EPH114 Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States

    Dec 1, 2025, 00:00

  • EPH203 Real-World Costs of United States Patients With T1 Diabetes, Removing Misdiagnosed Patients, and Compared With Patients With T1D and (T1.5 or T2) Diabetes

    Dec 1, 2025, 00:00

  • HPR134 Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025

    Dec 1, 2025, 00:00

  • HPR166 Public Spending on Medicines Between 2018 and 2026: Lessons for Designing a New Financing Model in Portugal

    Dec 1, 2025, 00:00

  • EE623 Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)

    Dec 1, 2025, 00:00

  • PCR69 Embedding Patient Experience Data (PED) in EU Joint Clinical Assessments: Strategic Imperatives and Evidence Practices

    Dec 1, 2025, 00:00

  • HPR194 The Clawbacks Paradox: When Abusing a Simple Approach Has the Most Complicated and Problematic Consequences for Patients and Healthcare Systems

    Dec 1, 2025, 00:00

  • EE138 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • EE199 Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective

    Dec 1, 2025, 00:00

  • SA46 Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study

    Dec 1, 2025, 00:00

  • P5 The Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in the US: A Total System Value Evidence Framework

    Dec 1, 2025, 00:00

  • HSD65 Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India

    Dec 1, 2025, 00:00

  • MSR202 The Statistical Abyss: Real-World Evidence for Health Technology Assessment

    Dec 1, 2025, 00:00

  • P57 Defining "Value" in Digital Health Interventions: A Triangulated Approach to Model Development

    Dec 1, 2025, 00:00

  • EE308 Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥ 65 Years in Italy

    Dec 1, 2025, 00:00

  • HPR22 Analysis of ATC Equivalent Group and Therapeutic Reference Code Distributions Based on Drug Price and Reimbursement Lists in Türkiye Between 2020 and 2025

    Dec 1, 2025, 00:00

  • PCR200 Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

    Dec 1, 2025, 00:00

  • EE237 Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland

    Dec 1, 2025, 00:00

  • P39 Seeking Patient and Public’s Opinions to Determine Target Differences in Clinical Trials: A Scoping Review of Elicitation Methods

    Dec 1, 2025, 00:00

  • MSR99 Evaluation of the Measurement Properties of the German LupusPRO™ for Swiss-German SLE Patients

    Dec 1, 2025, 00:00

  • MSR86 Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis (cLDA) for Patient-Reported Outcomes (PROs)

    Dec 1, 2025, 00:00

  • EE361 Economic Burden of Generalized Myasthenia Gravis (gMG) in Latin America (LA): A Microcosting Analysis of Direct Medical Costs (DMCs)

    Dec 1, 2025, 00:00

  • MSR173 Projected Rapid-Growing Economic Burden of Chronic Respiratory Multimorbidity in Singapore: Unveiling Diagnostic Gaps and Asian Phenotypes Through Health Administrative Data

    Dec 1, 2025, 00:00

  • EPH245 The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EE461 Faricimab vs. Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration: A Cost-Utility Analysis in Italy

    Dec 1, 2025, 00:00

  • MSR17 Agentic-AI Analyzer to Chat With Your Excel-Based Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • EE321 Design and Early Insights From the Pre-HDBOI Study: A Multicountry Real-World Assessment of the Burden in Pre-Motor Manifest Huntington’s Disease

    Dec 1, 2025, 00:00

  • P55 Choosing Appropriate Population-Adjusted Indirect Comparison Methods for Health Technology Assessment: A Simulation Study on the Impact of Effect Modifiers Baseline Imbalances and Sample Size

    Dec 1, 2025, 00:00

  • HTA347 Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions

    Dec 1, 2025, 00:00

  • EE580 Microsimulation Model to Estimate the Clinical and Cost Burden of Adverse Events Related to Long-Term Oral Corticosteroid Usage in Autoimmune Diseases in the United States

    Dec 1, 2025, 00:00

  • HTA367 What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?

    Dec 1, 2025, 00:00

  • HSD33 Differential Impact of Type 1 and Type 2 Diabetes on Families: A UK Cross-Sectional Study Using FROM-16

    Dec 1, 2025, 00:00

  • MSR129 Improving Efficiency in Evidence Synthesis: Performance Assessment of Machine Learning Classifiers for Automated Screening in Systematic Literature Reviews

    Dec 1, 2025, 00:00

  • EPH209 Screening for Chronic Kidney Disease (CKD): A Systematic Review and Meta-Analysis of Trials and Quasi Experimental Studies

    Dec 1, 2025, 00:00

  • PCR212 Satisfact-Home: Perception of Care Quality and Quality of Life in Patients With Solid Tumors Receiving Immune Checkpoint Inhibitors (ICIs) Therapy From Hospital To Home: A French Multicenter Prospective Observational Study

    Dec 1, 2025, 00:00

  • MSR187 Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage

    Dec 1, 2025, 00:00

  • RWD62 Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to the OMOP Common Data Model

    Dec 1, 2025, 00:00

  • EPH96 Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions

    Dec 1, 2025, 00:00

  • HTA266 Patient Preference Studies in HTA for Rare Diseases: A Cross-Country Analysis of EU-4, UK, and Canada

    Dec 1, 2025, 00:00

  • HPR225 Trends in EMA-Approved New Medicines 2015-2024: New Mechanisms of Action and Regulatory Shifts

    Dec 1, 2025, 00:00

  • HTA82 Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece

    Dec 1, 2025, 00:00

  • EE592 Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study

    Dec 1, 2025, 00:00

  • P19 Treatment Burden and Quality of Life in Patients With nAMD and DME in Colombia: A Mixed Methods Study

    Dec 1, 2025, 00:00

  • EE594 NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases

    Dec 1, 2025, 00:00

  • SA26 Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register

    Dec 1, 2025, 00:00

  • PCR73 Enhancing Patient Engagement in Consensus Development: Global Insights From a Targeted Review of Digital Platforms and Methods

    Dec 1, 2025, 00:00

  • EE555 Inpatient Burden of Influenza and Influenza-Like Illness Among Adults Aged 60 and Older in Germany 2019-2024

    Dec 1, 2025, 00:00

  • EE389 Economic Evaluation of the Breast Thermal Activity Indicator Plus Clinical Breast Examination

    Dec 1, 2025, 00:00

  • HPR71 Estimating Lost Life-Years and Quality-Adjusted Life-Years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England

    Dec 1, 2025, 00:00

  • HTA298 Similarities and Differences Between the National Institute for Health and Care Excellence (NICE) and European Union Joint Clinical Assessment (EU JCA) Clinical Systematic Literature Review Requirements

    Dec 1, 2025, 00:00

  • EPH226 Tendencies in the Public-Funded Hungarian One-Day Surgical Care

    Dec 1, 2025, 00:00

  • HTA2 A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies

    Dec 1, 2025, 00:00

  • EPH151 Is Greece on Track to Meet the 90% HPV Vaccine Coverage Rate Target by 2030? A Mathematical Modeling Study

    Dec 1, 2025, 00:00

  • EE755 When Cost-Effectiveness No Longer Counts: Industry Views on the Undermining of HTA Principles in Korea

    Dec 1, 2025, 00:00

  • MSR226 Workforce Matters: Defining Labor Input for Better Health Technology Assessment

    Dec 1, 2025, 00:00

  • HTA258 Nutrieconomics: Concept and Expert Consensus on Health Technology Assessment of Nutritional Interventions in Brazil

    Dec 1, 2025, 00:00

  • HPR208 The Landscape of Antibiotic Development and Regulation in the United States and Europe, Alongside Evolving Industry Incentive Strategies

    Dec 1, 2025, 00:00

  • EPH46 Clinical Functional Profile and Neuroimaging in Cerebral Palsy: A Population-Based Study

    Dec 1, 2025, 00:00

  • HPR169 Randomized Controlled Trials (RCTs) Are the Gold Standard: Are They Always Used?

    Dec 1, 2025, 00:00

  • OP1 Bridging the Gap Between AI Principles and Practi A Comparative Evaluation of AI Position Statements and Frameworks for Responsible Use

    Dec 1, 2025, 00:00

  • EE743 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Spain: A Return on Investment Analysis Using an Integrated Actuarial Macroeconomic Model

    Dec 1, 2025, 00:00

  • EE384 Economic Evaluation of Sodium Zirconium Cyclosilicate Lokelma for Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease in Egypt

    Dec 1, 2025, 00:00

  • RWD15 Air Pollution Signals and National Demand for Asthma Medication in Brazil Between 2018-2023: Should It Be Considered a Public-Health Concern?

    Dec 1, 2025, 00:00

  • EE460 Factors Associated With the Highest Costs Among US Adults With Primary Biliary Cholangitis

    Dec 1, 2025, 00:00

  • RWD112 Landscape of Data Sources for Real-World Observational Studies: Focus on the French Context

    Dec 1, 2025, 00:00

  • MSR133 Integrating Equity and Efficiency in Health Economic Evaluation: Development of Equity-Informed Methodologies in the French Healthcare Context (INEES Project)

    Dec 1, 2025, 00:00

  • EE558 Integrating Stakeholder Willingness-to-Pay Using the Van Westendorp Price Sensitivity Meter Into Cost-Effectiveness Analysis: A Mixed-Methods Pricing Framework

    Dec 1, 2025, 00:00

  • CO242 The Impact of Network Meta-Analyses on HTA Decisions in Oncology: A Review of NICE Appraisals

    Dec 1, 2025, 00:00

  • EE569 Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries

    Dec 1, 2025, 00:00

  • EE731 Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective

    Dec 1, 2025, 00:00

  • HSD56 Healthcare Costs in Older Adults: XGBoost, NNA, and Logit

    Dec 1, 2025, 00:00

  • EPH52 Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population

    Dec 1, 2025, 00:00

  • EE693 The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland

    Dec 1, 2025, 00:00

  • PCR144 Investigation of the Impact of Hereditary Angioedema (HAE) on Health-Related Quality of Life: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • MSR29 Application of Network Meta-Analysis in Vaccine Research: An Illustration Using Immunogenicity of Pneumococcal Vaccines in Adults

    Dec 1, 2025, 00:00

  • HPR158 Perceived Impact and Actionability of Barriers to Drug Repurposing: Insights From a Multistakeholder Policy Survey

    Dec 1, 2025, 00:00

  • RWD85 FLAME: An Open-Source Federated Platform for Deeply Phenotyped and Multimodal Studies at Population Scale

    Dec 1, 2025, 00:00

  • MSR84 Empirical Comparison of Four Approaches for Generating Confidence Intervals Around Weighted Trial-Level Correlation

    Dec 1, 2025, 00:00

  • PCR49 Comparing Health-Related Quality of Life in Obese Patients With and Without Bariatric Surgery: A Cross-Sectional Study in a Multi-Ethnic Asian Population in Singapore

    Dec 1, 2025, 00:00

  • MT31 National Competent Authorities’ Experiences With Early Feasibility Study Assessment: Promoting Dialogue, Supporting Sponsors, and Fostering Shared Learning to Harmonize the EU Framework

    Dec 1, 2025, 00:00

  • EE709 The Growing Importance of Reserve Antibiotics in Organ Transplant Care and the Role of Timely Appropriate Antibiotic Treatment to Preserve the Benefits of Prior Health Investments

    Dec 1, 2025, 00:00

  • CO231 Systematic Review of Prognostic Factors for Efficacy and Safety Outcomes in CAR-T Cell Therapy for Diffuse Large B-cell Lymphoma

    Dec 1, 2025, 00:00

  • RWD43 Comprehensive Landscape Assessment of Real-World Databases for HEOR Studies in the Asia-Pacific Region: A Growing Opportunity

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • CO61 Comparison of Bispecific T-cell Engager Antibodies and CAR-T Therapies for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • RWD165 Real-World Treatment Patterns of Locally Advanced and Metastatic Urothelial Cancer (la/MUC) in Fran A Secondary Database Analysis

    Dec 1, 2025, 00:00

  • CO147 Improving Pulmonary Tuberculosis Treatment Outcomes Through Pharmacist-Led Education: Findings From a Malaysian Randomized Control Trial

    Dec 1, 2025, 00:00

  • HTA205 Integrating Health Equity Into Health Technology Assessment: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR233 Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HTA180 How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions

    Dec 1, 2025, 00:00

  • CO55 Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR205 Real-World Drivers of Adherence in Obesity Highlight the Need for Patient-Centered Interventions

    Dec 1, 2025, 00:00

  • HPR224 Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25

    Dec 1, 2025, 00:00

  • HPR30 Assessing the Potential Impact of NICE’s Updated HST Routing Criteria on Ultraorphan Drugs

    Dec 1, 2025, 00:00

  • PCR76 EQ-5D Utility Trends in NMOSD: Impact of Time and Disability

    Dec 1, 2025, 00:00

  • HTA107 Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics

    Dec 1, 2025, 00:00

  • EE233 Cost-Effectiveness of Adjuvant Alectinib vs. Platinum-Based Chemotherapy in Resected Stage IB-IIIA ALK-Positive NSCLC: A French Health Economic Evaluation

    Dec 1, 2025, 00:00

  • HPR192 Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities

    Dec 1, 2025, 00:00

  • EPH253 The Relevance of the Use of TENS Devices in the Therapy of Poststroke Dysphagia

    Dec 1, 2025, 00:00

  • EPH168 Mutagenicity of Imazalil, Pyrimethanil, and Thiabendazole With and Without Citrus Oil

    Dec 1, 2025, 00:00

  • MSR48 Bootstrap Methods for Confidence Interval Estimation in Small Samples: Implications for Health Economics

    Dec 1, 2025, 00:00

  • RWD113 Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World (RW) Gastric Cancer (GC) Study

    Dec 1, 2025, 00:00

  • MSR192 Survival Model Uncertainty in Economic Modeling: Evaluating Bootstrap and Cholesky Decomposition Methods

    Dec 1, 2025, 00:00

  • HTA208 Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK

    Dec 1, 2025, 00:00

  • HSD82 Patient Blood Management Efficiency in Patients Subject to Orthopedic and Oncologic Elective Surgery

    Dec 1, 2025, 00:00

  • HTA145 Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics

    Dec 1, 2025, 00:00

  • EPH40 Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study

    Dec 1, 2025, 00:00

  • EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals

    Dec 1, 2025, 00:00

  • PCR209 Relevance of Quality Indicators for Supporting Patients’ Choice of Hospitals: An Online Survey

    Dec 1, 2025, 00:00

  • EE84 Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy

    Dec 1, 2025, 00:00

  • EE563 Launch Price Dynamics of Targeted Therapies in NSCLC: Dissecting the Cost and Value Across Biomarker Segments

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR244 The Use of Patient-Reported Experience Measures in Adults With Obstructive Sleep Apnea: A Systematic Evidence Review

    Dec 1, 2025, 00:00

  • EE70 Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal

    Dec 1, 2025, 00:00

  • RWD151 Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland in Comparison With Efficacy Reported in Clinical Trials

    Dec 1, 2025, 00:00

  • SA38 Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches

    Dec 1, 2025, 00:00

  • EE259 Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan

    Dec 1, 2025, 00:00

  • SA43 From Methods to Decisions: A Transparent Framework for Population-Adjusted Treatment Comparisons

    Dec 1, 2025, 00:00

  • HSD89 Population-Level Impact Assessment of the Revised Dyslipidemia Prescription Protocol in Greece Using Simulation Modeling

    Dec 1, 2025, 00:00

  • EE189 Cost Utility Analysis of a Digital Peer Navigation Program for Men With Prostate Cancer

    Dec 1, 2025, 00:00

  • HSD17 Burden of Healthcare Waste for European Hospitals: Findings From an AI-Based Literature Research

    Dec 1, 2025, 00:00

  • HTA248 Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions

    Dec 1, 2025, 00:00

  • P56 An Early Start: Preliminary Indirect Treatment Comparison Assessments Informing Evidence-Generation Planning for Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • CO148 Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • EPH280 Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco

    Dec 1, 2025, 00:00

  • EE510 Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • MSR115 Generation of Synthetic Patient Data to Overcome Machine Learning Limitations in Healthcare Research: A Systematic Review of Methods, Performance, and Use Cases

    Dec 1, 2025, 00:00

  • MSR196 The AI-Only Workflow: Model and Report Adaptation Without Human Setup

    Dec 1, 2025, 00:00

  • HPR190 Staying Competitive in a Crowded Vaccine Market: Is There Room for a Third or Fourth Entrant in the Same Disease Area?

    Dec 1, 2025, 00:00

  • MSR177 Qualitative Analysis of Results From a Delphi Study to Formalize a Treatment Protocol for Children With Early Diagnosed Duchenne Muscular Disease (DMD) Using Giles®, an Artificial Intelligence Agent for Healthcare Research

    Dec 1, 2025, 00:00

  • EE639 Real-World Healthcare Resource Utilization in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil Plus Bevacizumab or With Regorafenib

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • RWD53 Decoding Asthma: A Tale of Two Databases

    Dec 1, 2025, 00:00

  • HTA218 Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec

    Dec 1, 2025, 00:00

  • HPR94 Feasibility of Indication-Specific Pricing for Life Cycle Management of an Innovative Rare Disease Product

    Dec 1, 2025, 00:00

  • EE362 Economic Burden of Pneumococcal Disease—Impact of Age and Underlying Medical Conditions

    Dec 1, 2025, 00:00

  • EE446 Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist

    Dec 1, 2025, 00:00

  • HTA173 Health Technology Assessment (HTA) Systems and Risk Identification Strategies: A Comparative Analysis Across Western European Countries, Canada, and Australia

    Dec 1, 2025, 00:00

  • PCR248 Treatment Patterns and Healthcare Resource Utilization Among Patients With Immune Thrombocytopenia: A Real-World Survey

    Dec 1, 2025, 00:00

  • RWD107 Institutional Trends and Healthcare Resource Utilization in Real-World NMIBC and MIBC Treatment in Germany

    Dec 1, 2025, 00:00

  • HPR162 Predicting the Maximum Fair Price (MFP) From Medicare Negotiations

    Dec 1, 2025, 00:00

  • EE34 A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HTA31 Analysis of HTA Decisions in Five European Countries for High Medical Need Products Approved by EMA

    Dec 1, 2025, 00:00

  • HPR210 The New Discount on Combination Drug Therapies in Germany: First Numbers and Assessment From a Payor Perspective

    Dec 1, 2025, 00:00

  • HTA119 Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • P46 Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US

    Dec 1, 2025, 00:00

  • HTA289 Review of Surrogate Endpoints’ Acceptance Trends in German HTA and Implications for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • CO20 Association Between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR225 Win Ratio in the Presence of Censored Data: Can Probabilistic Variants Improve Robustness?

    Dec 1, 2025, 00:00

  • MSR141 Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications

    Dec 1, 2025, 00:00

  • EE129 Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium

    Dec 1, 2025, 00:00

  • EPH206 Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • EE408 Embracing the Long-Term in Disruptive Health Innovations: A Strategic Necessity or a Necessary Evil? Cost Utility of Langerhans Islet Grafting in Unstable Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HPR132 Leveling the Field: How the MFN Could Transform Drug Pricing

    Dec 1, 2025, 00:00

  • MSR205 Transportability of Overall Survival Estimates From the United States to Germany in eGFR+ Advanced NSCLC Patients Post-Tyrosine Kinase Inhibitor (TKI) Treatment

    Dec 1, 2025, 00:00

  • EE185 Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma

    Dec 1, 2025, 00:00

  • CO237 The Clinical Burden of Fractures in Osteogenesis Imperfecta: A Systematic Review

    Dec 1, 2025, 00:00

  • EE31 A Review of Indirect Costs Within Economic Appraisals in France

    Dec 1, 2025, 00:00

  • HTA284 Reimbursement Challenges for ATMPs in EU5: Learnings From Product Withdrawals and Implications for Future Development of Innovative Therapies

    Dec 1, 2025, 00:00

  • MSR47 BHM and BHM-Based Extrapolations in an HTA Framework

    Dec 1, 2025, 00:00

  • RWD154 Real-World Evidence in European Orphan Drug Submissions and the Impact on Reimbursement Success

    Dec 1, 2025, 00:00

  • CO260 Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma: A Real-World Observational Study

    Dec 1, 2025, 00:00

  • HTA213 Italian Perspective on Rare Disease New Treatments and HTA: Insights From Iptacopan Multidimensional Evaluation in PNH

    Dec 1, 2025, 00:00

  • EE50 Analysis of Social and Economic Burden of Type 1 Diabetes Care in Italy

    Dec 1, 2025, 00:00

  • MSR126 Identifying Risk Profiles for Early Treatment Discontinuation in Geographic Atrophy Using Machine Learning and SHAP Clustering

    Dec 1, 2025, 00:00

  • RWD143 Real-World Healthcare Resource Utilization and Related Costs Associated With Lung Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • EPH24 Associations Between Waiting Time and Treatment Completion Among Treatment-Naive Pregnant Cannabis Users Admitted to Treatment Facilities in the United States

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EE542 Impact of SGLT2-Inhibitor Uptake in CKD Management in Denmark: A Decision Economic Model

    Dec 1, 2025, 00:00

  • EE249 Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis

    Dec 1, 2025, 00:00

  • EE733 Transfusion-Related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective

    Dec 1, 2025, 00:00

  • HPR119 Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands

    Dec 1, 2025, 00:00

  • HTA78 Comparative Analysis of Reimbursement Landscapes: Advantages and Challenges of Bispecifics vs. CAR-T Therapies

    Dec 1, 2025, 00:00

  • EE711 The Impact of Adherence on the Value Assessment of Cardiovascular Interventions: A Systematic Literature Review of Economic Evaluations

    Dec 1, 2025, 00:00

  • EE340 Do We Need to Measure Social Impact of Innovative Drugs?

    Dec 1, 2025, 00:00

  • HPR34 Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective

    Dec 1, 2025, 00:00

  • HTA201 Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies

    Dec 1, 2025, 00:00

  • HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment Implications of EUHTA for Pharma: A Qualitative Exploration

    Dec 1, 2025, 00:00

  • EE211 Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • EE139 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • EE430 Evaluating Cost Benefits of Subcutaneous vs. Intravenous Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer Patients: From Qatari Healthcare Perspective

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • PCR79 Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?

    Dec 1, 2025, 00:00

  • HTA345 Uncertainty About How to Translate JCA Into National HTA Submissions (EU-4 and Poland): A Systematic Comparison From an Industry Perspective

    Dec 1, 2025, 00:00

  • EE318 Decision-Analytic Modeling on Imaging Modalities in Breast Cancer Staging: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • Table of Contents

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • EE168 Cost-Effectiveness of Belatacept as Conversion Therapy in the Management of Patients Living With a Renal Graft in France

    Dec 1, 2025, 00:00

  • EE226 Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden

    Dec 1, 2025, 00:00

  • MSR209 Understanding Drivers on Healthcare Resource Utilization Costs Among People Living With Obesity in UK Clinical Practice

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • HTA255 NICE Reduces Waiting Times for Technology Adoption: Early Value Assessment As a Pragmatic Approach to Adopting Promising Innovation in the NHS

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »